Welcome to our dedicated page for Neogenomics news (Ticker: NEO), a resource for investors and traders seeking the latest updates and insights on Neogenomics stock.
NeoGenomics, Inc. reports developments in oncology diagnostic testing, cancer genetics and information services. The company serves oncologists, pathologists, hospital systems, academic centers and pharmaceutical firms through cancer-focused laboratory testing, professional interpretation, clinical trial and research services, validation laboratory services and oncology data solutions.
Recurring news themes include clinical revenue trends, next-generation sequencing growth, reimbursement and coverage decisions, and additions to the company’s testing menu. Updates also cover products such as PanTracer LBx, PanTracer Tissue and RaDaR ST, electronic health record access through Epic Aura, research presentations using Oncology Data Solutions, and the operation of CAP-accredited and CLIA-certified laboratory capabilities in the United States and the United Kingdom.
NeoGenomics (NASDAQ:NEO) will participate in two investor conferences in late 2025: a company presentation at the Stephens Annual Investment Conference in Nashville on Wednesday, November 19, 2025 at 1:00 pm CT, and a fireside chat at the Piper Sandler 37th Annual Healthcare Conference in New York on Tuesday, December 2, 2025 at 2:30 pm ET.
Both sessions will offer live and archived webcasts available on the company’s Investor Relations site at ir.neogenomics.com.
NeoGenomics (NASDAQ: NEO) will present new research at the International Society of Liquid Biopsy (ISLB) Annual Congress 2025 showing high concordance between its RaDaR ST and RaDaR 1.0 assays for molecular residual disease (MRD) detection across solid tumors.
The bridging study evaluated matched samples from 166 patients across 15 solid tumor types, reporting 97% concordance and equivalent sensitivity for RaDaR ST versus RaDaR 1.0. RaDaR ST currently has Medicare coverage for HR+/HER2- breast cancer (recurrence monitoring >5 years after diagnosis) and HPV- head and neck carcinoma (adjuvant and recurrence monitoring). NeoGenomics expects the launch of RaDaR ST in Q1 2026 and will also present additional posters on whole genome–informed MRD, PanTracer LBx validation, and genomic profiling at ISLB 2025.
NeoGenomics (NASDAQ: NEO) reported third quarter 2025 results for the period ended September 30, 2025. Consolidated revenue rose 12% YoY to $188 million, driven by clinical revenue +18% and NGS revenue +24%, with NGS representing nearly one-third of clinical revenue. Revenue per clinical test increased 3% to $476. Net loss widened 53% to $27 million and Adjusted EBITDA fell 9% to $12.2 million. Cash and marketable securities totaled $164 million. The company re-affirmed full-year 2025 guidance of $720–$726 million revenue and retained its prior adjusted EBITDA and net loss ranges.
NeoGenomics (NASDAQ: NEO) will highlight its RaDaR ST molecular residual disease (MRD) circulating tumor DNA assay at the ESMO Congress 2025, October 17–21 in Berlin.
The company said RaDaR ST uses whole-exome sequencing from tumor samples plus advanced bioinformatics to create patient-specific MRD panels, applying high-depth sequencing and personalized design to sensitively detect ctDNA in plasma and track tumor dynamics and treatment response. NeoGenomics will present three new posters from European collaborators, note interventional therapy trials in progress, and feature RaDaR ST and broader oncology testing at booth #4012.
NeoGenomics (NASDAQ: NEO) will report third quarter 2025 financial results before U.S. market open on Tuesday, October 28, 2025. Management will host a webcast and conference call at 8:30 a.m. ET to discuss results and recent highlights.
Investors can access the live webcast via the company's Investor Relations site at ir.neogenomics.com. The webcast will be archived and available for replay. To join by phone, dial (888) 506-0062 (U.S.) or (973) 528-0011 (international) and use participant code 392611.
NeoGenomics (NASDAQ:NEO) has secured a significant legal victory as the District Court for the Middle District of North Carolina granted summary judgment in its patent infringement lawsuit against Natera. The Court ruled that Natera's asserted patent claims are invalid for claiming ineligible subject matter.
This ruling allows NeoGenomics to freely commercialize its RaDaR ST molecular residual disease (MRD) assay in the United States. The company has already launched RaDaR ST to biopharma customers and has submitted for clinical reimbursement coverage through CMS's MolDX program.
NeoGenomics (NASDAQ: NEO) has launched NEO PanTracer™ LBx, a blood-based comprehensive genomic profiling test designed for advanced solid tumors. The new test analyzes over 500 genes, including MSI and bTMB markers, with a 7-day turnaround time.
PanTracer LBx enables therapy selection, trial matching, and disease monitoring through a simple blood draw when tissue samples are limited or unavailable. This strategic launch positions NeoGenomics in the $3-5 billion liquid biopsy market, complementing their existing tissue-based testing portfolio and expanding their addressable market.
NeoGenomics (NASDAQ: NEO) reported Q2 2025 results with consolidated revenue increasing 10% to $181 million. Clinical revenue grew 16%, with 13% growth excluding the Pathline acquisition. The company's average revenue per clinical test increased 2% to $465, driven by higher-value tests and strategic reimbursement initiatives.
Despite revenue growth, NEO reported a net loss of $45 million, up 142% year-over-year, primarily due to $20 million in impairment charges. Adjusted EBITDA remained relatively flat at $10.7 million. The company completed the acquisition of Pathline for $8 million plus contingent consideration.
NeoGenomics revised its full-year 2025 guidance downward, now expecting revenue of $720-726 million (9-10% growth) and increased net loss projections to $108-116 million, citing pressure in pharma revenue and delays in the PanTracer™ Liquid Biopsy launch.
NeoGenomics (NASDAQ: NEO), a leading oncology diagnostic solutions provider, has scheduled its second quarter 2025 financial results announcement for July 29, 2025, before U.S. markets open. The company will host a conference call and webcast at 8:30 a.m. ET to discuss the results and recent highlights.
Investors can access the live webcast through the company's Investor Relations website at ir.neogenomics.com. For telephone access, participants can dial (888) 506-0062 (domestic) or (973) 528-0011 (international) using access code 859170.
NeoGenomics (NASDAQ: NEO) has launched PanTracer™ Tissue, a next-generation solid tumor profiling assay, along with PanTracer Tissue + HRD option for enhanced tumor analysis. The new assay evaluates over 500 cancer-related genes and can deliver results in as little as 8 days.
PanTracer Tissue + HRD specifically targets ovarian cancer diagnostics by incorporating homologous recombination deficiency analysis, BRCA mutation status, and genomic instability score in a single test. These biomarkers are crucial for guiding PARP inhibitor treatments and therapies targeting DNA repair pathways.
The new offerings, revealed at the 2025 ASCO Annual Meeting, represent an upgrade to the company's previous NeoComprehensive® Solid Tumor platform, featuring minimal specimen requirements and alignment with clinical guidelines for therapy selection and clinical trial enrollment.